139 related articles for article (PubMed ID: 36096572)
1. What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?
Weiss A; King TA
Adv Surg; 2022 Sep; 56(1):275-286. PubMed ID: 36096572
[TBL] [Abstract][Full Text] [Related]
2. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.
Kantor O; Wakeman M; Weiss A; Wong S; Laws A; Grossmith S; Mittendorf EA; King TA
Ann Surg Oncol; 2021 Mar; 28(3):1358-1367. PubMed ID: 32869154
[TBL] [Abstract][Full Text] [Related]
3. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
Schipper RJ; de Bruijn A; Voogd AC; Bloemen JG; Van Riet YE; Vriens BEP; Smidt ML; Siesling S; van der Sangen MJC; Nieuwenhuijzen GAP
Eur J Surg Oncol; 2021 Aug; 47(8):1928-1933. PubMed ID: 34030918
[TBL] [Abstract][Full Text] [Related]
4. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
6. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
Mukhtar RA; Hoskin TL; Habermann EB; Day CN; Boughey JC
Ann Surg Oncol; 2021 Oct; 28(11):5867-5877. PubMed ID: 33687613
[TBL] [Abstract][Full Text] [Related]
7. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
[TBL] [Abstract][Full Text] [Related]
8. Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Garufi G; Carbognin L; Arcanà C; Parola S; Ventriglia A; Doronzo A; Garutti M; Orlandi A; Palazzo A; Fabi A; Bria E; Tortora G; Arpino G; Giuliano M; Del Mastro L; De Laurentiis M; Puglisi F
Cancer Treat Rev; 2022 Nov; 110():102454. PubMed ID: 35987149
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives.
Sirico M; Virga A; Conte B; Urbini M; Ulivi P; Gianni C; Merloni F; Palleschi M; Gasperoni M; Curcio A; Saha D; Buono G; Muñoz M; De Giorgi U; Schettini F
Crit Rev Oncol Hematol; 2023 Jan; 181():103900. PubMed ID: 36565894
[TBL] [Abstract][Full Text] [Related]
10. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
[TBL] [Abstract][Full Text] [Related]
11. Characterizing Occult Nodal Disease Within a Clinically Node-Negative, Neoadjuvant Breast Cancer Population.
Hammond JB; Scott DW; Kosiorek HE; Parnall TH; Gray RJ; Ernst BJ; Northfelt DW; McCullough AE; Ocal IT; Pockaj BA; Cronin PA
Clin Breast Cancer; 2022 Feb; 22(2):186-190. PubMed ID: 34462208
[TBL] [Abstract][Full Text] [Related]
12. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
13. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies.
Poterala JE; Havighurst T; Braun Wisinski K
Clin Breast Cancer; 2022 Aug; 22(6):611-618. PubMed ID: 35676188
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
Korde LA; Somerfield MR; Carey LA; Crews JR; Denduluri N; Hwang ES; Khan SA; Loibl S; Morris EA; Perez A; Regan MM; Spears PA; Sudheendra PK; Symmans WF; Yung RL; Harvey BE; Hershman DL
J Clin Oncol; 2021 May; 39(13):1485-1505. PubMed ID: 33507815
[TBL] [Abstract][Full Text] [Related]
16. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Du L; Yau C; Brown-Swigart L; Gould R; Krings G; Hirst GL; Bedrosian I; Layman RM; Carter JM; Klein M; Venters S; Shad S; van der Noordaa M; Chien AJ; Haddad T; Isaacs C; Pusztai L; Albain K; Nanda R; Tripathy D; Liu MC; Boughey J; Schwab R; Hylton N; DeMichele A; Perlmutter J; Yee D; Berry D; Van't Veer L; Valero V; Esserman LJ; Symmans WF
Ann Oncol; 2021 May; 32(5):642-651. PubMed ID: 33617937
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer.
Lim DW; Greene BD; Look Hong NJ
Ann Surg Oncol; 2021 Oct; 28(10):5495-5506. PubMed ID: 34374914
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Endocrine Therapy in Clinical Practice: A Review.
Sella T; Weiss A; Mittendorf EA; King TA; Pilewskie M; Giuliano AE; Metzger-Filho O
JAMA Oncol; 2021 Nov; 7(11):1700-1708. PubMed ID: 34499101
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.
Weiss A; Wong S; Golshan M; Freedman RA; Metzger O; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Dec; 26(13):4326-4336. PubMed ID: 31562601
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
